Overview

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

Status:
Recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
Osteoporosis affects 24.5% of women over 65 and results in fracture-related hospital admissions exceeding those of heart attacks, strokes and breast cancer combined. Current treatment options do not account for differences between age-related and estrogen deficiency related osteoporosis, because of the need for bone biopsies for determination. This study will establish a paradigm-shifting individualized treatment protocol for age-related osteoporosis and a non-invasive method for its determination, thereby reducing the major health problems and enormous burden on society and the elderly related to this disease.
Phase:
Phase 4
Details
Lead Sponsor:
Hartmut Malluche, MD
Collaborator:
National Institute on Aging (NIA)
Treatments:
Alendronate
Teriparatide